• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Sub-minimum inhibitory concentrations of ceftibuten reduce adherence of Escherichia coli to human cells and induces formation of long filaments.

作者信息

Braga P C, Piatti G

机构信息

Center for Respiratory Pharmacology, School of Medicine, University of Milan, Italy.

出版信息

Microbiol Immunol. 1993;37(3):175-9. doi: 10.1111/j.1348-0421.1993.tb03197.x.

DOI:10.1111/j.1348-0421.1993.tb03197.x
PMID:8321147
Abstract

The minimal inhibitory concentrations (MICs) of an antibiotic are present for only a certain period of time, after which they become sub-inhibitory concentrations (sub-MICs). These sub-MICs are still active because they can interfere with the mechanism of bacterial adhesion, which is the first step in the sequence of events leading to infection. The purpose of the present study was to investigate the effects of sub-MICs of ceftibuten, a new third-generation cephalosporin, on the adhesion of Escherichia coli (E. coli) to human buccal cells. The degree of inhibition was maximal at 1/2 MIC and then gradually returned toward to the control values at 1/128 the MIC. The differences were statistically significant from 1/2 to 1/32 MIC. Since the MIC was 0.5 micrograms/ml, concentrations from 0.25 to 0.015 micrograms/ml significantly reduce bacterial adhesion. Ceftibuten also caused marked elongation of E. coli. These findings could help to explain the efficacy showed by ceftibuten in the treatment of respiratory and urinary tract infections when administered once daily.

摘要

相似文献

1
Sub-minimum inhibitory concentrations of ceftibuten reduce adherence of Escherichia coli to human cells and induces formation of long filaments.
Microbiol Immunol. 1993;37(3):175-9. doi: 10.1111/j.1348-0421.1993.tb03197.x.
2
Influence of enoxacin sub-MICs on the adherence of Staphylococcus aureus and Escherichia coli to human buccal and urinary epithelial cells.依诺沙星亚抑菌浓度对金黄色葡萄球菌和大肠杆菌黏附人颊黏膜及尿路上皮细胞的影响。
Chemotherapy. 1992;38(4):261-6. doi: 10.1159/000239009.
3
Kinetics of filamentation of Escherichia coli induced by different sub-MICs of ceftibuten at different times.
Chemotherapy. 1993 Jul-Aug;39(4):272-7. doi: 10.1159/000239136.
4
In vitro activity of ceftibuten at sub-inhibitory concentrations in comparison with other antibiotics against respiratory and urinary tract pathogens.与其他抗生素相比,头孢布烯在亚抑菌浓度下对呼吸道和泌尿道病原体的体外活性。
J Chemother. 2007 Apr;19(2):152-60. doi: 10.1179/joc.2007.19.2.152.
5
Favourable effects of sub-MIC rufloxacin concentrations in decreasing the pathogen-host cell adhesion.
Pharmacol Res. 1993 Jul-Aug;28(1):11-9. doi: 10.1006/phrs.1993.1105.
6
Staphylococcus aureus and Escherichia coli adhesion to human cells is reduced by sub-MICs of gemifloxacin.吉米沙星的亚抑菌浓度可降低金黄色葡萄球菌和大肠杆菌对人细胞的黏附。
J Chemother. 2002 Feb;14(1):41-6. doi: 10.1179/joc.2002.14.1.41.
7
Cefodizime: effects of sub-inhibitory concentrations on adhesiveness and bacterial morphology of Staphylococcus aureus and Escherichia coli: comparison with cefotaxime and ceftriaxone.
J Antimicrob Chemother. 1997 Jan;39(1):79-84. doi: 10.1093/jac/39.1.79.
8
Inhibition of bacterial adhesion by sub-inhibitory concentrations: brodimoprim vs trimethoprim.
J Chemother. 1993 Dec;5(6):447-52.
9
Interference by subinhibitory concentrations of azithromycin with the mechanism of bacterial adhesion to human epithelial cells.亚抑菌浓度阿奇霉素对细菌黏附人上皮细胞机制的干扰
Chemotherapy. 1993 Nov-Dec;39(6):432-7. doi: 10.1159/000238989.
10
Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.头孢布烯:抗菌活性、抗菌谱及其他微生物学特性综述
Pediatr Infect Dis J. 1995 Jul;14(7 Suppl):S77-83.

引用本文的文献

1
Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Drugs. 1994 May;47(5):784-808. doi: 10.2165/00003495-199447050-00006.